[REVISION HISTORY]
Iovance Biotherapeutics market performance
Updated 1 time since CLSTR started tracking revisions of this situation.
What changed
2026-09-30 04:34 UTC → 2026-10-07 05:02 UTC ·
added
removed
Iovance Biotherapeutics experienced significant stock growth driven by positive analyst sentiment and improved financial outlooks. Initially, shares reached a 52-week high following a Goldman Sachs upgrade to a ‘buy’ rating, with analysts citing the performance of the melanoma drug Amtagvi as a key driver. This momentum continued as the company sharply increased its 2026 revenue forecast, raising guidance to between $410 million and $420 million from a previous range of $350 million to $370 million. This upward revision, representing nearly 60% annual growth, is attributed to accelerating demand for Amtagvi and Proleukin, alongside the expansion of authorized treatment centers. centers, with a goal of reaching at least 110 centers by the end of the year. Following the revenue guidance update, H.C. Wainwright maintained a ‘Buy’ rating and significantly raised its price target for the stock from $9 to $20.
Versions
- 2026-10-07 05:02 UTC Iovance Biotherapeutics market performance
- 2026-09-30 04:34 UTC Iovance Biotherapeutics market performance
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.